GlassScriptPhysician profile
Jefferson T Gordon
NPI 1336167816
$7,691.04
in general payments reported to CMS, 2019-2025
45 companies · $827 in 2025
The $827 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $963 · 2021: $1,585 · 2022: $1,122 · 2023: $1,076 · 2024: $1,304 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,193 · Entertainment: $13.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.92 |
| Entertainment | $13.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,155.32 | 2019-2025 | |
| Novo Nordisk INC | $898.07 | 2019-2025 | Wegovy, Rybelsus |
| Pfizer INC. | $632.44 | 2019-2025 | |
| Lilly USA, LLC | $623.16 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $621.52 | 2019-2022 | |
| Amgen INC. | $549.47 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $420.56 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $340.37 | 2020-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $298.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $256.52 | 2020-2024 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.32 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $160.72 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.96 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.15 | 2019-2025 | Xifaxan |
| Eisai INC. | $98.14 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferson Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.